Myriad Genetics (MYGN) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Myriad Genetics published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Myriad Genetics reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted income (loss) per share, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• On October 19, 2026 Myriad Genetics agreed to sell its Prenatal Health business (Foresight, Prequel, FirstGene and SneakPeek) to Labcorp for $210 million in cash plus inventory at closing, expected by early 2027. Prenatal Health is still in Q3 2026 revenue.
• The year-ago adjusted income per share was $0.00 (shown as a dash in the release).

Source: Myriad Genetics Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Myriad Genetics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Myriad Genetics's Cancer Care Continuum revenue was $124 million in Q3 2026, up 1% from $123 million in Q3 2025, 61% of total revenue.
• Myriad Genetics's Mental Health revenue was $39.5 million in Q3 2026, up 2% from $38.7 million in Q3 2025, 19% of total revenue.
• Myriad Genetics's Prenatal Health revenue was $39.3 million in Q3 2026, down 12% from $44.5 million in Q3 2025, 19% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Myriad Genetics guides 2026 revenue of $780 million to $790 million: $620 million to $630 million from Cancer Care Continuum and Mental Health and about $160 million from Prenatal Health, with adjusted gross margin of 66% to 67%.

In its Q3 2026 release, Myriad Genetics said:

“Raised the mid-point of full-year 2026 revenue range, reflecting Q3 results and current business trends.”

“Lastly, we are increasing the mid-point of our full-year 2026 revenue guidance modestly, as we balance the positive third quarter 2026 performance with the timing of the sale of the Prenatal Health business, which is expected to close by early 2027.”

“Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends.”

Source: Myriad Genetics Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the MYGN forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and basic and diluted EPS, each as first reported in that quarter's release. Myriad Genetics published preliminary Q4 2025 revenue on January 12, 2026 and full results on February 23, 2026.

We do not hold a confirmed date for Myriad Genetics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Myriad Genetics' revenue was $202.7 million in Q3 2026, down 1% from $205.7 million but up 6% from Q2 2026. Cancer Care Continuum tests (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise Tumor and Precise MRD) brought in $123.9 million, the GeneSight mental health test $39.5 million and Prenatal Health $39.3 million. (Myriad Genetics Q3 2026 release, Nov 4, 2026)

Myriad's revenue is price times volume, and the two moved in opposite directions. Total test volume fell 2% to 377 thousand tests while average revenue per test rose 1%. The 10-Q says the $3.0 million revenue decline came from Prenatal Health, down $5.2 million on an 11% drop in volume, while Cancer Care Continuum rose $1.4 million on 4% more volume despite a 3% lower revenue per test, and Mental Health rose $0.8 million. (Myriad Genetics Q3 2026 release, Nov 4, 2026; Myriad Genetics Form 10-Q, Q3 2026, Nov 6, 2026)

Hereditary cancer testing revenue fell 1% because of lower reimbursement levels, even as volume rose 6%. Myriad said average revenue per hereditary cancer test improved 9% from Q2 2026 because of early progress on revenue cycle and payer engagement work. GeneSight revenue grew 2% on 3% more tests. (Myriad Genetics Q3 2026 release, Nov 4, 2026)

Reimbursement drives the business: about 61% of Myriad's revenue comes from private third-party payors, according to its 2025 10-K, with the rest from government programs such as Medicare and from patients. About 4% of revenue in the first nine months of 2026 was in currencies other than the dollar, mainly Japanese yen. (Myriad Genetics Form 10-K, 2025, Feb 24, 2026; Myriad Genetics Form 10-Q, Q3 2026, Nov 6, 2026)

Myriad Genetics lost $43.9 million, or $0.46 per share, in Q3 2026, against a loss of $27.4 million, or $0.29, a year earlier. The operating loss widened to $39.9 million from $23.3 million as gross margin fell 200 basis points to 67.9% and sales and marketing expense rose $12.9 million to $83.9 million, mostly from a $10.6 million increase in personnel costs for its commercial team. (Myriad Genetics Q3 2026 release, Nov 4, 2026; Myriad Genetics Form 10-Q, Q3 2026, Nov 6, 2026)

Myriad's adjusted loss per share was $0.11. The adjustments add back $12.6 million of strategic realignment costs such as severance and consulting fees, $9.2 million of equity compensation and $6.5 million of amortization of acquired intangibles, less a $4.9 million tax adjustment. (Myriad Genetics Q3 2026 release, Nov 4, 2026)

Myriad's weighted average share count rose to 95.7 million from 93.1 million. It did not repurchase any shares in the quarter. Interest expense was $4.1 million, and the variable-rate Credit Facility had a balance of $125.0 million. (Myriad Genetics Q3 2026 release, Nov 4, 2026; Myriad Genetics Form 10-Q, Q3 2026, Nov 6, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Myriad Genetics gives full-year non-GAAP guidance in its release. For 2026 it expects revenue of $780 million to $790 million, including $620 million to $630 million from Cancer Care Continuum and Mental Health and about $160 million from Prenatal Health, and an adjusted gross margin of 66% to 67%. It raised the mid-point of the revenue range after Q3, while factoring in the timing of the Prenatal Health sale to Labcorp, expected to close by early 2027. (Myriad Genetics Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Myriad Genetics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Myriad Genetics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning MYGN is on is MYGN a buy or a sell?, what analysts expect next is on the MYGN forecast, and what the company does is on the Myriad Genetics (MYGN) stock page.

Every number on this page can be traced to a document Myriad Genetics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.